Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT

Metformin in non-diabetic hyperglycaemia: the GLINT feasibility RCT

Background: The treatment of people with diabetes with metformin can reduce cardiovascular disease (CVD) and may reduce the risk of cancer. However, it is unknown whether or not metformin can reduce the risk of these outcomes in people with elevated blood glucose levels below the threshold for diabe...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Simon J Griffin, M Angelyn Bethel, Rury R Holman, Kamlesh Khunti, Nicholas Wareham, Gwen Brierley, Melanie Davies, Andrew Dymond, Rose Eichenberger, Philip Evans, Alastair Gray, Colin Greaves, Kyla Harrington, Graham Hitman, Greg Irving, Sarah Lessels, Ann Millward, John R Petrie, Martin Rutter, Mike Sampson, Naveed Sattar, Stephen Sharp
Formatua: Artikulua
Hizkuntza:English
Argitaratua: NIHR Journals Library 2018-04-01
Saila:Health Technology Assessment
Gaiak:
prevention
cardiovascular risk
cardiovascular disease
metformin
diabetes
type 2 diabetes
impaired glucose tolerance
hyperglycaemia
Sarrera elektronikoa:https://doi.org/10.3310/hta22180

Internet

https://doi.org/10.3310/hta22180

Antzeko izenburuak